SNDX - Syndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference
PR Newswire
WALTHAM, Mass. , Jan. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger , Chief Executive Officer of Syndax, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 10:30 a.m. PT / 1:30 p.m. ET .
A live webcast of the presentation can be accessed from the Investor section of the Company's website at www.syndax.com , where a replay of the event will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib (SNDX-5613), a highly selective inhibitor of the Menin–MLL binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn .
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
SOURCE Syndax Pharmaceuticals, Inc.
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.